Abundance of metabolites formed from lapatinib (50 μM) incubated with NADPH-fortified human liver microsomes (1 mg/ml), rCYP3A4, or rCYP3A5 (100 pmol/ml) for 30 minutes after ultracentrifugation and treatment with potassium ferricyanide (2 mM; 10 minutes) relative to abundance after ultracentrifugation in the absence of potassium ferricyanide
| Identity | Retention Time Relative to Lapatinib | Experimental m/za | HLM | rCYP3A4 + b5 | rCYP3A5 + b5 |
|---|---|---|---|---|---|
| % | |||||
| M1 | 0.50 | 473.1052 | 0 | 2.9 | 0.8 |
| M2 | 0.78 | 489.0995 | 0 | 0 | 0 |
| M3 | 0.95 | 597.1367 | 71.7 | 80.2 | 73.0 |
| M4 | 0.97 | 475.1336 | 82.0 | 78.5 | 79.8 |
| M5 | 1.10 | 613.1331 | 0 | 0 | 0 |
| M6 | 1.11 | 595.122 | 17.9 | 1.4 | 3.0 |
| M7 | 1.13 | 476.1176 | 100.2 | 88.4 | 96.0 |
| M8 | 1.14 | 597.1368 | 5.05 | 7.0 | 11.6 |
| M9 | 1.18 | 489.1125 | 195.3 | 125.4 | 87.5 |
| M10 | 1.21 | 474.1016 | 250.6 | 179.7 | 183.8 |
↵a Accurate m/z values and peak areas taken from the low energy MSE data set.